Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 676 participants.

Also called NCT02227550

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 676 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02227550
  • EudraCT 2014-002442-45
Other papers using this trial's data
  • MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial Circulation, 2022-03-22 DOI, PubMed 35135308

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Austria, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02227550. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Acronym
AXAFA
Intervention (Drug)
Vitamin K antagonist
Intervention (Drug)
Apixaban
Lead sponsor
Atrial Fibrillation Network (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)

Record details

Record id
cardio:ct-nct02227550
Content hash
1bfe02e38be512763bb0ddc965305df2ebd09ed36a03e4bc9572848719da4869